Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 13/20 | 0.70 |
| ▸ | DRD2 | P14416 | 7/20 | 0.67 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.61 |
| ▸ | HRH2 | P25021 | 2/20 | 0.60 |
| ▸ | HRH1 | P35367 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14453585 | 0.90 | KCNA5 (0.62) | DRD3DRD2KCNA5HRH2HRH1 | |
| SCHEMBL20423457 | 0.90 | DRD3 (0.55) | DRD3DRD2KCNA5HRH2HRH1 | |
| SCHEMBL1730771 | 0.89 | HRH2 (0.58) | DRD3DRD2KCNA5HRH2HRH1 | |
| SCHEMBL6034847 | 0.89 | HRH2 (0.61) | DRD3DRD2KCNA5HRH2HRH1 | |
| SCHEMBL14453658 | 0.89 | DRD3 (0.54) | DRD3DRD2KCNA5HRH2HRH1 | |
| SCHEMBL23301374 | 0.89 | DRD3 (0.54) | DRD3DRD2KCNA5HRH2HRH1 | |
| SCHEMBL18135536 | 0.88 | KCNA5 (0.64) | DRD3DRD2KCNA5ALDH1A1 | |
| SCHEMBL25747712 | 0.88 | GPR4 (0.56) | DRD3DRD2KCNA5HRH2HRH1 | |
| SCHEMBL31319939 | 0.87 | MAOB (0.56) | DRD3DRD2KCNA5HRH2HRH1 | |
| SCHEMBL29716350 | 0.86 | LTA4H (0.56) | DRD3DRD2KCNA5HRH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12145922-B2 | Selective D3 dopamine receptor agonists and methods of their use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-11-19 | — | — | US | disclosed |
| US-20230312511-A1 | SELECTIVE D3 DOPAMINE RECEPTOR AGONISTS AND METHODS OF THEIR USE | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2023-10-05 | — | — | US | disclosed |
| US-20230312511-A1 | SELECTIVE D3 DOPAMINE RECEPTOR AGONISTS AND METHODS OF THEIR USE | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2023-10-05 | — | — | US | disclosed |
| US-11634404-B2 | Selective D3 dopamine receptor agonists and methods of their use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-04-25 | — | — | US | disclosed |
| US-20210323941-A1 | SELECTIVE D3 DOPAMINE RECEPTOR AGONISTS AND METHODS OF THEIR USE | THE UNIVERSITY OF KANSAS | 2021-10-21 | — | — | US | disclosed |
| EP-3442955-B1 | SELECTIVE D3 DOPAMINE RECEPTOR AGONISTS AND METHODS OF THEIR USE | US HEALTH (US) | 2021-09-29 | — | — | EP | disclosed |
| WO-2017181004-A1 | SELECTIVE D3 DOPAMINE RECEPTOR AGONISTS AND METHODS OF THEIR USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12145922-B2 | Selective D3 dopamine receptor agonists and methods of their use | SLC6A3, DRD3, DRD2 | DRD3 2/4885DRD2 3/4885KCNA5 1791/4885 |
| US-20210323941-A1 | SELECTIVE D3 DOPAMINE RECEPTOR AGONISTS AND METHODS OF THEIR USE | SLC6A3, DRD3, CHRM2 | DRD3 2/4885DRD2 4/4885KCNA5 1509/4885 |
| US-20230312511-A1 | SELECTIVE D3 DOPAMINE RECEPTOR AGONISTS AND METHODS OF THEIR USE | SLC6A3, DRD3, DRD2 | DRD3 2/4885DRD2 3/4885KCNA5 1791/4885 |
| US-11634404-B2 | Selective D3 dopamine receptor agonists and methods of their use | SLC6A3, DRD3, CHRM2 | DRD3 2/4885DRD2 4/4885KCNA5 1509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.